Journal of Oncology / 2018 / Article / Tab 1

Research Article

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

Table 1

Comparison of baseline clinicopathological demographics among treatment groups (N=158).

VariablesN (%) or mean±sd or median (min-max)

Age (miss=1, years)58.62±10.64
Gender, Male/Female124 (78.5)/34 (21.5)
Metastatic type, Synchronous/Metachronous97 (61.4)/61 (38.6)
Body mass index (miss=13)23.70±3.27
KPS (miss=19), KPS >80127 (91.4)
      KPS ≤8012 (8.6)
Nephrectomy89 (56.3)
ECOG baseline (miss=1) 0/1+2+3/unknown75 (47.8)/64 (40.8)/18 (11.5)
Underlying disease, Diabetes (miss=1)37 (23.6)
        Hypertension (miss=1)73 (46.5)
        Cerebrovascular disease6 (3.8)
        Cardiac disease4 (2.5)
Duration from the first-line treatment (months)4.8 (1.0-70.4)
Disease free interval (months)2.0 (0.0-240.0)
Disease free interval≤1 year106 (67.1)
MSKCC new (miss=52) favorable/intermediate/poor13 (12.3)/75 (70.8)/18 (17)
Heng new (miss=26) favorable/intermediate/poor14 (10.6)/94 (71.2)/24 (18.2)
Metastatic Organ, Lung metastasis113 (71.5)
       Liver metastasis (miss=1)33 (21)
       Lymph node metastasis69 (43.7)
       Bone metastasis (miss=1)54 (34.4)
       Brain metastasis (miss=5)18 (11.8)
Number of metastatic organs (miss=6)2.20±0.96
Baseline laboratory parameters
 Leukocyte (miss=4) ≥1029 (18.8)
 Hemoglobin (miss=4) M<13, F<11.590 (58.4)
 Platelet (miss=4) ≥400K19 (12.3)
 Neutrophil (miss=6) <7500/124 (81.6)
 Neutrophil lymphocyte ratio2.68 (0.77-39.2)
 Lymphocyte (miss=4) ≥150094 (61)
 LDH (miss=41) ≥30013 (11.1)
 Corrected Calcium (miss=9) ≥1011 (7.4)
 Albumin (miss=10) <3.523 (15.5)
 Alkaline phosphatase (miss=14) ≥10450 (34.7)
 AST (miss=10) ≥4012 (8.1)
 ALT (miss=10)≥40)18 (12.2)
 De Retis ratio1.38±0.92
 Creatinine (miss=7) ≥0.9134 (88.7)
Targeted agents TKI (miss=1), sunitinib, sorafenib, pazopanib105 (66.9)/21 (13.4)/31 (19.8)
First line treatment result continue/PD/AE/unknown9 (5.7)/129 (81.7)/11 (7)/9 (5.7)
Survival (%)17.70%
Progression (%)98.10%

KPS, Karnofsky performance status score; ECOG, Eastern Cooperative Oncology Group performance status; MSKCC, Memorial Sloan Kettering Cancer Center; LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine transaminase.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.